Jalathi Surendran Nair

Title: Jalathi Surendran Nair: Innovator in Anticancer Research

Introduction

Jalathi Surendran Nair is a prominent inventor based in Bengaluru, India. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target cancer-related pathways. With a total of 2 patents, his work is paving the way for new therapeutic options in oncology.

Latest Patents

Nair's latest patents include innovative compounds designed to inhibit specific protein kinases. The first patent focuses on "Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors." This invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. These compounds inhibit protein kinase activity, making them useful as anticancer agents. The second patent is for "Substituted pyrazolo-piperazines as casein kinase 1 δ/ε inhibitors." Similar to the first, this invention also provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, which inhibit protein kinase activity and serve as potential anticancer agents.

Career Highlights

Jalathi Surendran Nair is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research in the pharmaceutical industry. His work is characterized by a strong focus on developing innovative solutions for cancer treatment.

Collaborations

Nair collaborates with talented professionals in his field, including Upender Velaparthi and Chetan Padmakar Darne. These collaborations enhance the research efforts and contribute to the successful development of new therapeutic agents.

Conclusion

Jalathi Surendran Nair is a dedicated inventor whose work in anticancer research is making a significant impact. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.